Insider filing · WVE

GSK plc bought $22.3M of Wave Life Sciences (WVE)

Executed Sep 27 2024, disclosed Oct 1 2024, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Oct 1 2024), the stock returned +81.4% (delay-adjusted); from the execution session (Sep 27 2024), +73.1%. Derived: entry at the session's open, exit at the close 20 sessions later.

GP GSK plc 10% owner profile →

GSK plc (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in WVE. Across 1 priced purchase filing, the average 21-session return was -29.8% from execution and -13.4% from disclosure (delay-adjusted; derived). The largest single filing was $27.9M of WVE (1,470,000 sh × $19.00, as filed), executed Dec 11 2025.

WVE WVE WVE · 26 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→